Literature DB >> 24331182

Current advances in immunotherapy for pancreatic cancer.

Jennifer N Uram, Dung T Le.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24331182      PMCID： PMC4203151          DOI： 10.1016/j.currproblcancer.2013.10.004

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  30 in total

1.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

Authors:  P Argani; C Iacobuzio-Donahue; B Ryu; C Rosty; M Goggins; R E Wilentz; S R Murugesan; S D Leach; E Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

2.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

3.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 4.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

5.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Authors:  Richard Herrmann; György Bodoky; Thomas Ruhstaller; Bengt Glimelius; Emilio Bajetta; Johannes Schüller; Piercarlo Saletti; Jean Bauer; Arie Figer; Bernhard Pestalozzi; Claus-Henning Köhne; Walter Mingrone; Salomon M Stemmer; Karin Tàmas; Gabriela V Kornek; Dieter Koeberle; Susanne Cina; Jürg Bernhard; Daniel Dietrich; Werner Scheithauer
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

6.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

7.  Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Authors:  Udaya K Liyanage; Todd T Moore; Hong-Gu Joo; Yoshiyuki Tanaka; Virginia Herrmann; Gerard Doherty; Jeffrey A Drebin; Steven M Strasberg; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

8.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

9.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.

Authors:  S L Bernhardt; M K Gjertsen; S Trachsel; M Møller; J A Eriksen; M Meo; T Buanes; G Gaudernack
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

10.  Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Authors:  Amy Morck Thomas; Lynn M Santarsiero; Eric R Lutz; Todd D Armstrong; Yi-Cheng Chen; Lan-Qing Huang; Daniel A Laheru; Michael Goggins; Ralph H Hruban; Elizabeth M Jaffee
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307
View more
  6 in total

Review 1.  Pancreatic cancer-improved care achievable.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

2.  Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.

Authors:  Moitza Principe; Simone Borgoni; Mariafrancesca Cascione; Michelle Samuel Chattaragada; Sammy Ferri-Borgogno; Michela Capello; Sara Bulfamante; Jennifer Chapelle; Francesca Di Modugno; Paola Defilippi; Paola Nisticò; Paola Cappello; Chiara Riganti; Stefano Leporatti; Francesco Novelli
Journal:  J Hematol Oncol       Date:  2017-01-13       Impact factor: 17.388

Review 3.  Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jiang Chen; Guo Xiao-Zhong; Xing-Shun Qi
Journal:  J Immunol Res       Date:  2017-02-07       Impact factor: 4.818

Review 4.  Immunotherapy for pancreatic cancer.

Authors:  Elias Kotteas; Muhammad Wasif Saif; Konstantinos Syrigos
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-03       Impact factor: 4.322

Review 5.  Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies.

Authors:  Alexander B Dillon; Kevin Lin; Andrew Kwong; Susana Ortiz
Journal:  AIMS Public Health       Date:  2015-03-24

Review 6.  Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making?

Authors:  Stavros Gkolfinopoulos; Demetris Papamichael; Konstantinos Papadimitriou; Panos Papanastasopoulos; Vassilios Vassiliou; Panteleimon Kountourakis
Journal:  World J Gastrointest Oncol       Date:  2018-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.